Ultimately, any biopharma or medical device company’s success depends on its ability to make the right decisions at the right time. Cytel’s Quantitative Strategies and Data Science group helps customers transform data into robust decisions, minimizing development risks and increasing the chances of bringing new, effective therapies to patients, faster.
Our Quantitative Strategies & Data Science team comprises Statisticians, Data Scientists, Computer Scientists, Geneticists, Operations Research Scientists, Health Economists, Biomedical Engineers, Epidemiologists, and Pharmacometricians with an ability to achieve objectives in creative and effective ways. Our Strategic Consultants keep abreast of emerging trends in the industry and across regulators, adapting precedent and developing innovative solutions to meet the specific needs of each project. The team impartially selects and combines traditional and novel approaches enabling smart, efficient clinical development and reimbursement for biopharma and device companies of all sizes. The team interacts across six practice lines: